{
    "clinical_study": {
        "@rank": "14815", 
        "acronym": "EPCAT II", 
        "arm_group": [
            {
                "arm_group_label": "rivaroxaban", 
                "arm_group_type": "Active Comparator", 
                "description": "rivaroxaban 10mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients"
            }, 
            {
                "arm_group_label": "ASA", 
                "arm_group_type": "Experimental", 
                "description": "ASA 81mg x 9 days for total knee arthroplasty patients; x 30 days for total hip athroplasty patients"
            }
        ], 
        "brief_summary": {
            "textblock": "In this study the investigators want to look at whether using aspirin instead of rivaroxaban\n      (after initial treatment with rivaroxaban) works as well at preventing blood clots while\n      also reducing risk of bleeding and is more cost effective in patients who have either a\n      total hip replacement or total knee replacement."
        }, 
        "brief_title": "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Venous Thromboembolism Prevention", 
        "condition_browse": {
            "mesh_term": [
                "Thromboembolism", 
                "Venous Thromboembolism", 
                "Venous Thrombosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        1.  All patients undergoing elective total hip or knee arthroplasty at the participating\n        institutions will be potentially eligible for this study\n\n        Exclusion Criteria:\n\n          1. Hip or lower limb fracture in the previous three months\n\n          2. Metastatic cancer\n\n          3. Life expectancy less than 6 months\n\n          4. History of major bleeding that in the judgment of the investigator precludes use of\n             anticoagulant prophylaxis\n\n          5. History of aspirin allergy, active peptic ulcer disease or gastritis that in judgment\n             of investigator precludes use of aspirin\n\n          6. History of significant hepatic disease or any other condition that in the judgement\n             of the investigator precludes the use of rivaroxaban\n\n          7. Creatinine clearance less than 30 ml per minute\n\n          8. Platelet count less than 100 x 109 /L\n\n          9. Need for long-term anticoagulation due to a preexisting co-morbid condition or due to\n             the development of venous thromboembolism following surgery but prior to\n             randomization\n\n         10. Did not or will not receive rivaroxaban post-operatively for VTE prophylaxis\n\n         11. Bilateral total hip arthroplasty or simultaneous hip and knee arthroplasty\n\n         12. Major surgical procedure within the previous three months\n\n         13. Requirement for major surgery post arthroplasty within 90 day period\n\n         14. Chronic daily aspirin use with dose greater than 100 mg a day\n\n         15. Women of child bearing potential who are not abstinent or do not use appropriate\n             contraception throughout the study drug period\n\n         16. Geographical inaccessibility for follow-up\n\n         17. Unwilling or unable to give consent\n\n         18. Previous participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "3426", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720108", 
            "org_study_id": "EPCATII.001"
        }, 
        "intervention": {
            "arm_group_label": [
                "rivaroxaban", 
                "ASA"
            ], 
            "intervention_name": "rivaroxaban and ASA", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 11, 2014", 
        "location": {
            "contact": {
                "email": "susan.pleasance@cdha.nshealth.ca", 
                "last_name": "Susan Pleasance, BScN", 
                "phone": "902-473-7585"
            }, 
            "facility": {
                "address": {
                    "city": "Halifax", 
                    "country": "Canada", 
                    "state": "Nova Scotia", 
                    "zip": "B3H 3A7"
                }, 
                "name": "Capital Health"
            }, 
            "investigator": {
                "last_name": "Michael Dunbar, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty", 
        "overall_official": {
            "affiliation": "Capital District Health Authority, Canada", 
            "last_name": "David R Anderson, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "symptomatic venous thromboembolism", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "major or clinically relevant non-major bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720108"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Capital District Health Authority, Canada", 
            "investigator_full_name": "David Anderson", 
            "investigator_title": "Head, Department of Medicine, CDHA", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "survival", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "stroke", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "wound infection", 
                "safety_issue": "No", 
                "time_frame": "up to 4 years"
            }, 
            {
                "measure": "cost-effectiveness", 
                "safety_issue": "Yes", 
                "time_frame": "up to 4 years"
            }
        ], 
        "source": "Capital District Health Authority, Canada", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Institutes of Health Research  (CIHR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "David Anderson", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}